EMN29

Title

A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

Study map

Overview / Summary

Study details

Participating countries are:

Germany (Prof.  Katja Weisel from Hamburg as study PI and country coordinator) – active

Italy (Prof. Antonietta Falcone from San Giovanni Rotondo as country coordinator) – active

Greece (Prof. Evangelos Terpos from Athens as country coordinator) – active

France (Prof. Philippe Moreau from Nantes as country coordinator)

Netherland (Prof. Ruth Wester from Rotterdam as country coordinator) – active

Spain (Prof. Paula Rodriguez Otero from Pamplona as country coordinator) – active

United States – active

 

 

 

Patient eligibility criteria

Pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an IMiD, PI and an anti-CD38 mAb.

Publications